Aquatic Capital Management LLC Arvinas, Inc. Transaction History

Aquatic Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$36.38 - $52.31 $523,872 - $753,264	14,400 New	14,400 $594,000
Q3 2023 Nov 14, 2023	BUY	$19.64 - $28.21 $47,136 - $67,704	2,400 New	2,400 $47,000
Q1 2023 May 15, 2023	SELL	$26.15 - $37.26 $128,135 - $182,574	-4,900 Reduced 46.23%	5,700 $156,000
Q4 2022 Feb 14, 2023	BUY	$32.47 - $57.24 $344,182 - $606,744	10,600 New	10,600 $362,000
Q2 2022 Aug 15, 2022	BUY	$36.01 - $74.24 $61,217 - $126,207	1,700 New	1,700 $72,000
Q1 2022 May 16, 2022	SELL	$60.27 - $81.57 $36,162 - $48,941	-600 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$65.85 - $96.21 $39,510 - $57,725	600 New	600 $49,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Aquatic Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aquatic Capital Management LLC with notifications on news.